Regeneron (NASDAQ: REGN) furnishes Q4 and full-year 2025 results

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Regeneron Pharmaceuticals, Inc. filed a current report to furnish a press release announcing its financial and operating results for the fourth quarter and full year ended December 31, 2025. The press release is included as Exhibit 99.1 to the report.

The company states that the information provided under the results section, including Exhibit 99.1, is being furnished rather than filed under securities laws, which affects how it is treated for certain legal liabilities and incorporation by reference into other registration statements.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

01/30/2026 - 06:51 AM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 30, 2026

REGENERON PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)


New York	000-19034	13-3444607
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)


777 Old Saw Mill River Road, Tarrytown, New York 10591-6707
(Address of Principal Executive Offices, including zip code)

(914) 847-7000

Registrant's telephone number, including area code

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock - par value $.001 per share	REGN	NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On January 30, 2026, Regeneron Pharmaceuticals, Inc. issued a press release announcing its financial and operating results for the quarter and year ended December 31, 2025. A copy of the press release is being furnished to the Securities and Exchange Commission as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference to this Item 2.02.

The information included or incorporated in this Item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall such information and exhibit be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

99.1 Press Release, dated January 30, 2026, Reporting Fourth Quarter and Full Year 2025 Financial and Operating Results.

104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: January 30, 2026	REGENERON PHARMACEUTICALS, INC.

	By:	/s/ Joseph J. LaRosa
	Name:	Joseph J. LaRosa
	Title:	Executive Vice President, General Counsel and Secretary

Source: View Original Filing on SEC EDGAR

FAQ

What did Regeneron (REGN) disclose in its latest 8-K filing?

Regeneron disclosed that it issued a press release announcing its financial and operating results for the quarter and year ended December 31, 2025. The release is furnished as Exhibit 99.1, providing investors with detailed quarterly and full-year performance information.

Which period do Regeneron (REGN)'s reported results in this 8-K cover?

The results described relate to Regeneron’s financial and operating performance for the quarter and full year ended December 31, 2025. These time frames indicate both the most recent quarter and the complete fiscal year are addressed in the accompanying press release.

How is the Regeneron (REGN) earnings press release treated under securities laws?

Regeneron specifies that the information in Item 2.02 and Exhibit 99.1 is being furnished, not filed, under the Exchange Act. This means the material is generally not subject to certain liabilities and is not automatically incorporated into Securities Act filings.

What exhibits are included in Regeneron (REGN)'s January 30, 2026 8-K?

The filing includes Exhibit 99.1, a press release dated January 30, 2026 reporting fourth quarter and full year 2025 financial and operating results. It also includes Exhibit 104, which provides the cover page interactive data file with embedded Inline XBRL tags.

Who signed the January 30, 2026 Regeneron (REGN) 8-K report?

The report was signed on behalf of Regeneron Pharmaceuticals, Inc. by Joseph J. LaRosa. He is identified in the filing as Executive Vice President, General Counsel and Secretary, indicating a senior legal and corporate governance role at the company.